Abstract
The emergence of GIPR:GLP-1R co-agonists has heralded a renaissance of anti-obesity medication. In the recent SURMOUNT 2 trial, Garvey and colleagues ......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
